Mucosal healing with thiopurines has been poorly investigated in ulcerative colitis (UC).
Dr Caroline Prieux-Klotz and colleagues assessed mucosal healing rate in UC patients treated with thiopurine monotherapy.
The researchers retrospectively collected all UC patients treated with thiopurines more than 6 months who have undergone colonoscopy at baseline, and after at least 6 months of treatment.
Patients were recruited from 2005 to 2015 through a personal database and/or standardized hospital inpatient diagnostic dataset.
Patients were excluded in case of any use of other immunomodulator or biological agent.
|Mucosal healing was achieved in 44%|
|Digestive Diseases & Sciences|
The research team defined mucosal healing as a Mayo endoscopic subscore ≤1 and UCEIS ≤ 2.
Histological healing was defined by the absence of epithelial polynuclear infiltrate, cryptic abscesses, or ulcerations.
The researchers included 80 patients, with a median disease duration of 11 years.
At baseline, median full Mayo score, endoscopic subscore, and UCEIS were 8, 3, and 5, respectively.
Mucosal healing was first assessed after a mean follow-up of 38 months.
The research team found that the median full Mayo score, endoscopic subscore, and UCEIS decreased to 3.5, 2, and 2, respectively.
Mucosal healing was achieved in 44%, and histological healing in 38%.
The researchers identified that predictors of mucosal healing were thiopurine exposure duration ≥2 years, and a prior acute severe colitis.
Factors associated with MH during treatment were partial Mayo score ≤2, BMI ≥ 25 kg/m2, and MCV ≥ 95 fL.
Dr Prieux-Klotz's team commented, "In UC, thiopurine monotherapy is associated with mucosal healing in 44%, and histological healing in 38%."